ABSTRACT
Introduction: COPD patients are considered at risk of severe COVID-19 illness, however there are limited data on the burden of COVID-19 disease in this patient population. This study investigated the rate of COVID-19 diagnosis and hospitalization for COPD due to COVID-19 (pre-vaccination) over time, stratified by disease severity. Method(s): A retrospective cohort of COPD patients aged >=35 years, FEV1/FVC score <0.7, indexed from Mar-Aug 2020, using the English Clinical Practice Research Datalink Aurum database and Hospital Episode Statistics datasets. Monthly incidence rates of COVID-19 diagnosis and overall inpatient hospitalizations were described for all patients and by GOLD 2019 disease grade. Result(s): The study identified 103,105 COPD patients (mean [SD] age: 69.6 [10.6] years, 54.1% males) with 42.0%, 25.9%, 4.5%, and 6.3% in GOLD A, GOLD B, GOLD C, and GOLD D disease grade groups respectively, in the 12 months prior to index. Results over time are shown in Figure 1. Incidence rates of COVID-19 hospitalization (95% CI) per 100,000 person-days for the Mar-Aug period were GOLD A (2.2 [1.9, 2.6]), GOLD B (4.7 [4.1, 5.4]), GOLD C (4.6 [3.2, 6.3]), and GOLD D (7.9 [6.3, 9.7]). Conclusion(s): Among COPD patients, COVID-19 incidence peaked in April 2020. COVID-19 hospitalization rates were significantly higher in patients with more severe COPD and highest in GOLD D group patients. (Figure Presented).
ABSTRACT
S79 Figure 1ConclusionAmong patients with COPD in routine clinical practice in England, the frequency of moderate and severe exacerbations declined between January 2020 and April 2020 for most stratification groups and remained low through to August 2020. When comparing GOLD grade at baseline, the proportion of patients to experience an exacerbation increased with increasing disease severity grade.Please refer to page A211 for declarations of interest related to this abstract.
ABSTRACT
S75 Figure 1ConclusionAmong patients with asthma, the frequency of severe exacerbations declined steeply between March 2020 and May 2020 for all stratification groups and remained low through to August 2020. When comparing GINA step at baseline, a higher proportion of patients in GINA steps 4 and step 5 experienced a severe exacerbation compared with patients in GINA steps 1/2, step 2 and step 3 throughout the observation period. Further research on the long-term impact of COVID-19 on asthma exacerbations in routine clinical practice in England is warranted.Please refer to page A211 for declarations of interest related to this .
ABSTRACT
S39 Figure 1ConclusionAmong patients with asthma, COVID-19 diagnosis rates peaked in April 2020, declined steeply to June 2020 and remained low through to August 2020. COVID-19 hospitalisation rates were substantially higher in patients with more severe asthma and highest among patients in GINA step 5 treatment group. Future studies on the long-term impact of COVID-19 in asthma are warranted.Please refer to page A209 for declarations of interest related to this .